Antihypertensive effect of combination therapy of telmisartan and low dose hydrochrolthiazide in hypertemnsive patients

Phase 4

• Conditions: Severe hypertensive patients with uncontrolled hypertension

• Registration Number: JPRN-UMIN000000798
• Lead Sponsor: on profit Organization LINE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-08-15
• Study Completion: 2008-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1) Endocrine hypertension 2) Severe hypertension with office systolic blood pressure over 180mmHg and/or diastolic blood pressure over 90mmHg 3) Malignant hypertension 4) Continuous ventricular tachycardia or severe arrythmia (AV block II-III, Af etc) 5) Severe heart failure (NYHA III-IV) 6) Myocardial Infarction, Coronary bypass surgery, and Intervention therapy were performed within 6 months 7) Patients with exclusion criteria of amlodipine, telmisartan and hedrochrolthiazide 8) Serum creatinine >2.1mg/dl 9) Serum potassium >5.5mEq/l or <3.5mEq/l 10) Untreated hyperuricemia or treated hyperuricemia with UA>8.0mg/dl 11) ACEI, ARB and Diuretic treated patients 12) Uncontrolled diabetic patients (HbA1c>9.0%) and diabetic patients with insulin injection 13) Hypoglycemia 14) Hypersensitivity with telmisartan and hydrochrolthiazide 15) Patients who are inadequate to entry this study by physicians in charge

Study & Design

• Study Type: Interventional
• Study Design: Not specified